收藏切换
Analysis of the safety reporting requirements of drug clinical trial institutions in China
收藏切换
Da-wei WU1, An-qi YU1, Zhao YAN2, Wen-na CHEN3, Yue-long GU3, Hui-yao HUANG1, Hong FANG1, Hui WANG1, Qi-yu TANG1, Zhen-gang XU1, Yu TANG1, Ning LI1
Chinese Journal of New Drugs | 2021, 30(16) : 1503 - 1508
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(16): 1503-1508
Analysis of the safety reporting requirements of drug clinical trial institutions in China
Full
Da-wei WU1, An-qi YU1, Zhao YAN2, Wen-na CHEN3, Yue-long GU3, Hui-yao HUANG1, Hong FANG1, Hui WANG1, Qi-yu TANG1, Zhen-gang XU1, Yu TANG1, Ning LI1
Affiliations
  • 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • 2Continuing Education and Science & Technology Service Department of China Anti-Cancer Association, Tianjin 300384, China
  • 3Guangzhou Jeeyor Medical Research Co., Ltd., Guangzhou 510805, China
Published: 2021-08-30
Outline
收藏切换
Objective:

To summarize and analyze the current situation of safety reporting requirements of drug clinical trial institutions in China after the implementation of the new “Good Clinical Practice” (GCP).

Methods:

Data processing and statistical analysis were conducted on the reporting procedures and management requirements of safety events issued by 98 drug clinical trial institutions.

Results:

Fifty institutions (51.0%) required investigators to submit suspected unexpected serious adverse reactions (SUSAR) to ethics committees. A high proportion of institutions did not specify the media and time limit for SUSAR submission. There were 36 (36.7%) institutions that differentiated the time limit for SUSAR submission from sponsors to at least one role of investigators, ethics or trial management departments. The time limit for SUSAR at own hospitals was shorter than that from other hospitals and 7 or 15 d was the most common time limit. Forty-two (42.9%) institutions required investigators to report severe adverse events (SAE) to ethics committees and/or trial management departments.

Conclusion:

Drug clinical trial institutions have timely updated the safety reporting requirements which focus on SUSAR and other safety events at own hospitals. It is necessary to further improve the clarity and convenience of safety reporting procedures and explore the management mechanism of safety events at the institution level.

drug clinical trial institution  /  good clinical practice  /  safety report  /  suspected and unexpected serious adverse reaction
吴大维, 于安琪, 阎昭, 陈文娜, 古月龙, 黄慧瑶, 房虹, 王辉, 汤骐羽, 徐震纲, 唐玉, 李宁. 我国药物临床试验机构安全性报告要求的现状分析. 中国新药杂志, 2021 , 30 (16) : 1503 -1508 .
Da-wei WU, An-qi YU, Zhao YAN, Wen-na CHEN, Yue-long GU, Hui-yao HUANG, Hong FANG, Hui WANG, Qi-yu TANG, Zhen-gang XU, Yu TANG, Ning LI. Analysis of the safety reporting requirements of drug clinical trial institutions in China[J]. Chinese Journal of New Drugs, 2021 , 30 (16) : 1503 -1508 .
Year 2021 volume 30 Issue 16
53
7
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-08-30
Article Data
Affiliations
History
  • Accepted:2021-04-21
Affiliations
    1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2Continuing Education and Science & Technology Service Department of China Anti-Cancer Association, Tianjin 300384, China
    3Guangzhou Jeeyor Medical Research Co., Ltd., Guangzhou 510805, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT